CoronaryAtlas logo
CoronaryAtlas
Interleukin-6
Pathway / Plaque inflammation

Interleukin-6

IL6protein

IL-6 promotes plaque inflammation and leukocyte recruitment, accelerating atherosclerotic instability and thrombotic risk.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleCore inflammatory cytokine; plaque destabilization via macrophage activation.
Druggability
DruggableYes
Known drugs / candidates6
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000136244

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
61
A — assay feasibility
72
E — evidence strength
55
T1DI (composite)
21
Specificity differential (R−C)+6.1
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 2
3sudden cardiac deathmag 1
4aPCI-related periproceduralmag 2
4bstent thrombosismag 2
4cin-stent restenosismag 1
5CABG-relatedmag 2
Coverage: 11/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 23 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Chemiluminescent sandwich immunoassay / ELISA
Reagent / substrate
Anti-IL-6 antibody pair
Platform
Automated (Roche/Siemens) or ELISA plate
Turnaround · availability
Same-day–send-out · FDA-cleared (Roche Elecsys IL-6)

Human genetic evidence

0.268
Open Targets association (acute_MI)

Literature evidence(60)

Showing 40 of 60 linked references.

Clinical trials(1)